Allogene Therapeutics, Inc. (ALLO) financial statements (2020 and earlier)

Company profile

Business Address 210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:602721
Cash and cash equivalents16192
Short-term investments340367
Other undisclosed cash, cash equivalents, and short-term investments101262
Prepaid expense23
Other undisclosed current assets(94)(257)
Total current assets:510468
Noncurrent Assets
Property, plant and equipment469
Long-term investments and receivables101262
Long-term investments101262
Intangible assets, net (including goodwill)01
Intangible assets, net (excluding goodwill)01
Restricted cash and investments41
Other noncurrent assets30
Other undisclosed noncurrent assets3133
Total noncurrent assets:186306
TOTAL ASSETS:696774
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities812
Accounts payable812
Deferred compensation liability35
Other liabilities21
Other undisclosed current liabilities2112
Total current liabilities:3329
Noncurrent Liabilities
Liabilities, other than long-term debt914
Deferred compensation liability, classified57
Other liabilities57
Other undisclosed noncurrent liabilities3328
Total noncurrent liabilities:4241
Total liabilities:7671
Stockholders' equity
Stockholders' equity attributable to parent620703
Common stock00
Additional paid in capital953914
Accumulated other comprehensive income20
Accumulated deficit(335)(212)
Total stockholders' equity:620703
TOTAL LIABILITIES AND EQUITY:696774

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
Operating expenses(170)(193)
Operating loss:(170)(193)
Nonoperating income (expense)16(19)
Other nonoperating income186
Interest and debt expense (3)
Loss from continuing operations before equity method investments, income taxes:(154)(215)
Other undisclosed income from continuing operations before income taxes33
Loss from continuing operations before income taxes:(151)(212)
Income tax benefit00
Other undisclosed income from continuing operations0 
Loss before gain (loss) on sale of properties:(151)(212)
Other undisclosed net loss(3) 
Net loss available to common stockholders, diluted:(154)(212)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
Net loss:(154)(212)
Other comprehensive loss (0)
Other undisclosed comprehensive loss(0) 
Comprehensive loss:(154)(212)
Other undisclosed comprehensive income, net of tax, attributable to parent20
Comprehensive loss, net of tax, attributable to parent:(152)(211)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: